Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
NCT07524322
This study is recruiting at 5 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a phase 1/1b, open-label, multicenter study consisting of sequential parts designed to evaluate the safety, tolerability, and effects pharmacokinetic (PK) profile, and antitumor activity of RGT-490, an investigational oral therapy, in adults with locally advanced or metastatic solid tumors including breast cancer. Participants enrolled in the study have advanced disease that is not amendable to curative treatment and whose tumors harbor alterations in the PI3KCA gene.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Breast Cancer
- Ovarian Cancer
- Endometrial Cancer
- PIK3CA Mutation
- HER2- Negative Breast Cancer
- Advanced Breast Cancer
- Unresectable Solid Tumor
- Hormone Receptor Positive Tumor
- Cervical Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Regor Pharmaceuticals Inc.
- Last updated on ClinicalTrials.gov
- July 22, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- START Los Angeles · Los Angeles, CA
Texas · 3
- NEXT Houston · Houston, TX
- The University of Texas MD Anderson Cancer Center · Houston, TX
- NEXT San Antonio · San Antonio, TX
Virginia · 1
- NEXT Virginia · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.